NASDAQ:SIBN SI-BONE (SIBN) Stock Forecast, Price & News $20.78 -0.41 (-1.93%) (As of 10/3/2023 ET) Add Compare Share Share Today's Range$20.69▼$21.3550-Day Range$20.22▼$25.7652-Week Range$11.14▼$29.51Volume280,515 shsAverage Volume308,079 shsMarket Capitalization$803.98 millionP/E RatioN/ADividend YieldN/APrice Target$28.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability SI-BONE MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside34.7% Upside$28.00 Price TargetShort InterestHealthy2.17% of Shares Sold ShortDividend StrengthN/ASustainability-1.44Upright™ Environmental ScoreNews Sentiment0.95Based on 2 Articles This WeekInsider TradingSelling Shares$2.02 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.25) to ($0.93) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.16 out of 5 starsMedical Sector454th out of 966 stocksSurgical & Medical Instruments Industry54th out of 98 stocks 3.5 Analyst's Opinion Consensus RatingSI-BONE has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.00, SI-BONE has a forecasted upside of 34.7% from its current price of $20.78.Amount of Analyst CoverageSI-BONE has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.17% of the outstanding shares of SI-BONE have been sold short.Short Interest Ratio / Days to CoverSI-BONE has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SI-BONE has recently increased by 13.16%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSI-BONE does not currently pay a dividend.Dividend GrowthSI-BONE does not have a long track record of dividend growth. Previous Next 3.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSI-BONE has received a 34.81% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Cervical implants" product. See details.Environmental SustainabilityThe Environmental Impact score for SI-BONE is -1.44. Previous Next 2.7 News and Social Media Coverage News SentimentSI-BONE has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for SI-BONE this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for SIBN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added SI-BONE to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SI-BONE insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,015,672.00 in company stock.Percentage Held by InsidersOnly 5.40% of the stock of SI-BONE is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for SI-BONE are expected to grow in the coming year, from ($1.25) to ($0.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SI-BONE is -15.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SI-BONE is -15.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSI-BONE has a P/B Ratio of 7.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About SI-BONE (NASDAQ:SIBN) StockSI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and distributors. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.Read More SIBN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SIBN Stock News HeadlinesSeptember 27, 2023 | americanbankingnews.comCantor Fitzgerald Reaffirms "Overweight" Rating for SI-BONE (NASDAQ:SIBN)September 8, 2023 | finance.yahoo.comHas SiBone (SIBN) Outpaced Other Medical Stocks This Year?October 4, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 6, 2023 | finance.yahoo.comDoes Si-Bone (SIBN) Have the Potential to Rally 39.93% as Wall Street Analysts Expect?September 5, 2023 | finance.yahoo.comSI-BONE, Inc. Announces iFuse Bedrock Granite® Implant System Compatibility with Certain Medtronic CD Horizon® Solera® 5.5/6.0 System RodsAugust 31, 2023 | msn.comSI-BONE: Another Record Quarter, Reinvesting For Future Growth, Reiterate BuyAugust 29, 2023 | finance.yahoo.comSI-BONE To Present at Morgan Stanley 21st Annual Global Healthcare Conference on September 12, 2023August 27, 2023 | msn.comMorgan Stanley bullish on SI-Bone, downgrades Stevanato, Integra, AgilitiOctober 4, 2023 | Porter and Company (Ad)Top Analyst Exposes Imminent Crisis Hurtling Towards AmericaThe man who warned of the dot-com blow up, the 2008 housing collapse, and the loss of America’s AAA rating makes a shocking prediction…August 9, 2023 | finance.yahoo.comSI-BONE, Inc. (NASDAQ:SIBN) Q2 2023 Earnings Call TranscriptAugust 9, 2023 | msn.comCantor Fitzgerald Reiterates SI-BONE (SIBN) Overweight RecommendationAugust 8, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: SI-Bone (SIBN) and Enanta Pharmaceuticals (ENTA)August 8, 2023 | finance.yahoo.comSI-BONE, Inc. Reports Financial Results for the Second Quarter 2023 and Increases Annual GuidanceJuly 19, 2023 | msn.comTruist Securities Maintains SI-BONE (SIBN) Buy RecommendationJuly 19, 2023 | finance.yahoo.comSI-BONE to Present at Canaccord Genuity 43rd Annual Growth Conference on August 9, 2023July 17, 2023 | finance.yahoo.comSI-BONE To Report Second Quarter 2023 Financial Results on August 7, 2023July 16, 2023 | markets.businessinsider.comTruist Financial Sticks to Their Buy Rating for SI-Bone (SIBN)July 12, 2023 | msn.comNeedham Maintains SI-BONE (SIBN) Buy RecommendationJuly 12, 2023 | markets.businessinsider.comSI-BONE Poised For A Surge: Analyst Highlights Upside Potential With New Product LaunchesJuly 7, 2023 | fool.comSi-bone (NASDAQ: SIBN)June 15, 2023 | msn.comSI-BONE: Rating Higher On Fundamental, Economic GroundsJune 14, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Bioxcel Therapeutics (BTAI), SI-Bone (SIBN)May 31, 2023 | msn.comMorgan Stanley Maintains SI-BONE (SIBN) Overweight RecommendationMay 29, 2023 | finance.yahoo.comDespite shrinking by US$86m in the past week, SI-BONE (NASDAQ:SIBN) shareholders are still up 69% over 1 yearMay 24, 2023 | finance.yahoo.comSI-BONE To Present at Jefferies 2023 Healthcare Conference on June 7, 2023May 10, 2023 | msn.comUnusual Call Option Trade in SI-BONE (SIBN) Worth $65.00KMay 2, 2023 | finance.yahoo.comWhy Shares of Si-Bone Jumped TuesdaySee More Headlines Receive SIBN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SI-BONE and its competitors with MarketBeat's FREE daily newsletter. Email Address SIBN Company Calendar Last Earnings8/07/2023Today10/03/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SIBN CUSIPN/A CIK1459839 Webwww.si-bone.com Phone(408) 207-0700FaxN/AEmployees357Year Founded2008Price Target and Rating Average Stock Price Forecast$28.00 High Stock Price Forecast$33.00 Low Stock Price Forecast$20.00 Forecasted Upside/Downside+34.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-61,260,000.00 Net Margins-38.32% Pretax Margin-38.32% Return on Equity-40.35% Return on Assets-27.29% Debt Debt-to-Equity Ratio0.20 Current Ratio11.68 Quick Ratio10.55 Sales & Book Value Annual Sales$106.41 million Price / Sales7.56 Cash FlowN/A Price / Cash FlowN/A Book Value$2.85 per share Price / Book7.29Miscellaneous Outstanding Shares38,690,000Free Float36,597,000Market Cap$803.98 million OptionableNot Optionable Beta0.96 Social Links The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMs. Laura A. Francis MBA (Age 56)CEO & Director Comp: $1.11MMr. Anshul Maheshwari (Age 43)Chief Financial Officer Comp: $614.25kMr. Anthony J. Recupero (Age 64)Pres of Commercial Operations Comp: $795.32kMr. Jeff BertoliniSr. VP of Operations & Information TechnologyDr. Scott A. Yerby (Age 55)Sr. VP of Engineering & CTO Mr. Michael A. Pisetsky (Age 45)Chief Bus. & Legal Affairs Officer Ms. Aimee EinsteinVP of People & CultureDr. Daniel Joseph Cher (Age 58)Sr. VP of Clinical & Regulatory Affairs Dr. W. Carlton Reckling (Age 61)Chief Medical Officer & VP of Medical Affairs Mr. Nikolas F. Kerr (Age 51)Sr. VP of Product, Strategy & Bus. Devel. More ExecutivesKey CompetitorsTreace Medical ConceptsNASDAQ:TMCIOrthoPediatricsNASDAQ:KIDSBeauty HealthNASDAQ:SKINEmbectaNASDAQ:EMBCAtrionNASDAQ:ATRIView All CompetitorsInsiders & InstitutionsBarclays PLCSold 3,695 shares on 9/21/2023Ownership: 0.038%Jeffrey W DunnSold 20,000 sharesTotal: $452,200.00 ($22.61/share)California State Teachers Retirement SystemBought 3,817 shares on 8/21/2023Ownership: 0.109%Osaic Holdings Inc.Bought 3,581 shares on 8/21/2023Ownership: 0.011%Orion Portfolio Solutions LLCBought 8,793 shares on 8/17/2023Ownership: 0.023%View All Insider TransactionsView All Institutional Transactions SIBN Stock - Frequently Asked Questions Should I buy or sell SI-BONE stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SI-BONE in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SIBN shares. View SIBN analyst ratings or view top-rated stocks. What is SI-BONE's stock price forecast for 2023? 7 Wall Street research analysts have issued 1-year price targets for SI-BONE's stock. Their SIBN share price forecasts range from $20.00 to $33.00. On average, they anticipate the company's share price to reach $28.00 in the next twelve months. This suggests a possible upside of 34.7% from the stock's current price. View analysts price targets for SIBN or view top-rated stocks among Wall Street analysts. How have SIBN shares performed in 2023? SI-BONE's stock was trading at $13.60 at the beginning of 2023. Since then, SIBN stock has increased by 52.8% and is now trading at $20.78. View the best growth stocks for 2023 here. When is SI-BONE's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our SIBN earnings forecast. How were SI-BONE's earnings last quarter? SI-BONE, Inc. (NASDAQ:SIBN) released its quarterly earnings results on Monday, August, 7th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.11. The company had revenue of $33.31 million for the quarter, compared to analyst estimates of $32.24 million. SI-BONE had a negative trailing twelve-month return on equity of 40.35% and a negative net margin of 38.32%. What guidance has SI-BONE issued on next quarter's earnings? SI-BONE updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $132.00 million-$134.00 million, compared to the consensus revenue estimate of $130.03 million. What is Jeffrey Dunn's approval rating as SI-BONE's CEO? 10 employees have rated SI-BONE Chief Executive Officer Jeffrey Dunn on Glassdoor.com. Jeffrey Dunn has an approval rating of 41% among the company's employees. This puts Jeffrey Dunn in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of SI-BONE own? Based on aggregate information from My MarketBeat watchlists, some companies that other SI-BONE investors own include CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), RTX (RTX), Thermo Fisher Scientific (TMO), Verizon Communications (VZ), Alibaba Group (BABA), Cisco Systems (CSCO) and CSX (CSX). When did SI-BONE IPO? (SIBN) raised $84 million in an initial public offering (IPO) on Wednesday, October 17th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers. What is SI-BONE's stock symbol? SI-BONE trades on the NASDAQ under the ticker symbol "SIBN." How do I buy shares of SI-BONE? Shares of SIBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is SI-BONE's stock price today? One share of SIBN stock can currently be purchased for approximately $20.78. How much money does SI-BONE make? SI-BONE (NASDAQ:SIBN) has a market capitalization of $803.98 million and generates $106.41 million in revenue each year. The company earns $-61,260,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis. How many employees does SI-BONE have? The company employs 357 workers across the globe. Does SI-BONE have any subsidiaries? The following companies are subsidiares of SI-BONE: SI-BONE Deutschland GmbH, SI-BONE S.R.L., and SI-BONE UK LTD.Read More How can I contact SI-BONE? SI-BONE's mailing address is 471 EL CAMINO REAL SUITE 101, SANTA CLARA CA, 95050. The official website for the company is www.si-bone.com. The company can be reached via phone at (408) 207-0700 or via email at investors@si-bone.com. This page (NASDAQ:SIBN) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SI-BONE, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.